

Subclinical Atherosclerosis in
Patients with Systemic Sclerosis

Thesis

*Submitted for Partial Fulfillment of Master Degree
in Internal Medicine*

By

Emad Ahmed Ahmed M. Hassan

M.B., B.Ch.

Faculty of Medicine – Ain Shams University

Supervised by

Prof. Dr. Adel Mahmoud Ali

Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

Dr. Mervat Mamdouh Abo-Gabal

Assistant Professor of Internal Medicine

Faculty of Medicine - Ain Shams University

Dr. Sherin Mohammed Hosney

Lecturer of Internal Medicine

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

٢٠٠٩

Acknowledgment

First and foremost, thanks to God to Whom I relate my success in achieving this work,....

I would like to express my deepest gratitude to Prof. Dr. Adel Mahmoud Ali, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for his continuous encouragement, patience, and generous guidance.....

Also Dr. Mervat Mamdouh Abo-Gabal, Assistant Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for her valuable effort, generous guidance and endless support that ultimately led to the completion of the work in the possible best form.

I would like to offer my deep gratitude and sincere thanks to Dr. Sherine Mohamed Hosny Hamza, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University, for her continuous assistance, and unlimited guidance...

I would also like to thank Dr. Hanan Owais, for her continuous assistance, and valuable efforts exerted to complete this work...

Lastly, I shall never forget to thank our patients who willingly recruited themselves to serve in the accomplishment of this work...

List of Contents

Title	Page
• List of Tables.....	ii
• List of Figures.....	iv
• Abbreviation.....	v
• Introduction.....	١
• Aim of the Work	٣
• Review of Literature:	
○ Systemic Sclerosis	٤
○ Atherosclerosis and Endothelial Dysfunction	٧٢
○ Vascular Diseases in Systemic Sclerosis	١٠٦
• Subjects and Methods.....	١٣٢
• Results.....	١٤١
• Discussion.....	١٦٠
• Summary and Conclusion	١٦٨
• Recommendations.....	١٧١
• References	١٧٢
• Arabic Summary	--

List of Tables

Tab. No	Subjects	Page
١.	Scleroderma subdivisions	٢٨
٢.	Descriptive analysis of the commonest clinical findings in SSc patients.....	١٤٣
٣.	Descriptive analysis of the autoantibody profile in SSc patients	١٤٤
٤.	Descriptive analysis of the capillary microscopic score and stage in SSc patients.....	١٤٤
٥.	Descriptive analysis of drug therapy in SSc patients	١٤٥
٦.	Descriptive data of our ٢٠ SSc patients (group I).....	١٤٦
٧.	Descriptive data of the ١٠ healthy controls (group II).....	١٤٧
٨.	Comparative study between patients and controls as regard some cardiovascular risk factors	١٤٨
٩.	Comparison between patients and controls as regard vascular function.....	١٤٩
١٠.	Comparison between SSc patients and control subject as regard common carotid artery IMT	١٥٠
١١.	Comparison between SSc patients with normal IMT and increased IMT	١٥١
١٢.	Comparison between SSc patients with normal IMT and increased IMT as regard ESR and capillary microscopic score	١٥٣

List of Tables (Cont.)

Tab. No	Subjects	Page
١٣.	Comparison between capillary microscopic stages (active, early and late) as regard vascular endothelial function and IMT in all SSc patients	١٥٤
١٤.	Correlation between IMT and different parameters in all patients	١٥٥
١٥.	Correlation between IMT in all patients with ESR ١st hour, and capillary microscopic score	١٥٦
١٦.	Correlation between IMT and different parameters in patients with increased IMT	١٥٨
١٧.	Correlation between IMT with ESR ١st hour, and capillary microscopic score in patients with increased IMT	١٥٩

List of Figures

Fig. No	Subjects	Page
١.	Regulation of vascular tone by the endothelium	٩٣
٢.	Different invasive and non-invasive methodologies to asses endothelial dysfunction in patients with cardiovascular risk factors.....	١٠١
٣.	The normal nailfold capillaroscopic pattern	١١٤
٤.	The giant capillary pattern in nailfold capillaroscopy	١١٥
٥.	Local microhaemorrhages in nailfod capillaroscopy	١١٦
٦.	Tortuous capillary pattern in nailfod capillaroscopy	١١٧
٧.	Capillary loss pattern nailfod capillaroscopy	١١٨
٨.	Discorganization of normal architectural pattern in nailfod capillaroscopy	١١٩
٩.	The “scleroderma pattern” early, active and late patterns nailfod capillaroscopy	١٢١
١٠.	The percentage of clinical signs and symptoms in systemic sclerosis patients.....	١٤٢
١١.	Comparison between IMT in patients and controls.....	١٥٠
١٢.	Correlative study between age and carotid IMT	١٥٦
١٣.	Correlative study between disease duration and carotid IMT.....	١٥٧

List of Abbreviations

ABPI	Ankle brachial pressure index
ACA	Anticentromere antibodies
ACE	Angiotensic converting enzyme
ACH	Acetyl choline
aCLs	Anticardiolipin antibodies
ACR	American college of rheumatology
ADNA	Asymmetric dimethylarginine
AECA	anti-endothelial cell antibodies
AFA	anti-fibroblast antibodies
ANA	Anti-nuclear antibody
ANCA	anti-neucleocytoplasmic antibody
Anti-FBN- γ	anti-fibrillin- γ antibodies
Anti-PM-Scl	anti-polymyositis-scleroderma antibodies
Anti-RNAP	anti-RNA polymerase antibodies
anti-RNP	anti- ribonucleoprotein antibody
Anti-Scl- γ	anti-scleroderma- γ
Anti-Th/To antibodies	Antibodies to Th/To ribonucleoprotein
Anti-Topo I	anti-topoisomerase I antibody
Anti-U α -RNP	anti-U α -ribonucleoprotein antibodies
aOxLDL	anti-oxidised low density lipoprotein antibody
aPLS	antiphospholipid antibodies
APS	Antiphospholipid syndrome
ATP	Adenosine triphosphate
BAL	Bronchioalveolar lavage
bFGF	basic fibroblast growth factor
BH γ	Dihydrobioprotein

List of Abbreviations (Cont.)

BH ₂	Tetrahydrobiopterin
CAC	Coronary artery calcification
CAD	Coronary artery disease
CCA	Common carotid artery
CCL ₂	Chemokine (C-C motif) ligand 2
CEC	Circulating endothelial cells
CFR	Coronary flow reserve
cGK-I	Cyclic GMP-dependent kinase I
cGMP	Cyclic guanosine monophosphate
CI	Confidence interval
CMV	Cytomegalovirus
CREST	Calcinosis, Raynaud's phenomenon, sclerodactyle, telangiectasia
CRP	C-reactive protein
CTGF	Connective tissue growth factor
dcSSc	diffuse cutaneous systemic sclerosis
DM	Diabetes mellitus
DOCA	Desoxycorticosterone acetate
EBCT	Electron beam computed tomography
ECG	Electrocardiography
EDCF	Endothelium derived constricting factor
EDRF	Endothelium derived relaxing factor
ELAM	Endothelial leukocyte adhesion molecule
EMPs	Endothelial microparticles
eNOS	endothelial nitric oxide synthase
EPC	Endothelial progenitor cells
EScSG	European scleroderma study group

List of Abbreviations (Cont.)

ET	Endothelin
EUSTAR	Eular scleroderma trials and research
EULAR	European league against rheumatism
FMD	Flow mediated vasodilatation
GFR	Glomerular filtration rate
HAV	Hepatitis A virus
HDL	High density lipoproteins
HLA	Human leukocytic antigen
HMG-Co-A	Hydroxy methyl glutaryl Co-A
HRCT	High-resolution computed tomography
HSP	Heat shock protein
HSV	Herpes simplex virus
ICAM	Intracellular adhesion molecules
IFN- α	Interferon gamma
IGF	Insulin-like growth factor
IIF	Indirect immunefluorescence
IL	Interleukin
IL γ	Inositol triphosphate
ILD	Interstitial lung disease
IMT	Intima media thickness
IRAG	Inositol triphosphate-receptor-associated G-kinase substrate
IVIGs	Intravenous immunoglobulins
JRA	Juvenile rheumatoid arthritis
kD	kiloDalton
lcSSc	Limited cutaneous systemic sclerosis
LDL	Low density lipoprotein

List of Abbreviations (Cont.)

LFA	Lymphocyte function associated antigen
L-NAME	Notro-L-arginine methyl ester
L-NMMA	Notroglycerine monomethyl-L-arginine
Lp(a)	Lipoprotein (a)
MCP	Monocyte chemotactic protein
MMP	anti-extracellular matrix metalloproteinase antibodies
MRCA	Magnetic resonance coronary angiography
MRP	Mitochondrial RNA processing
MRSS	Modified Rodnan skin score
NAD	Nicotinamide dinucleotide
NADPH	Nicotinamide adenosine dinucleotide phosphate
NK	Natural killer cells
NMD	Nitrate mediated vasodilatation
NO	Nitric oxide
NOS	Nitric oxide synthase
NSIP	Nonspecific interstitial pneumonitis
NTG	Nitroglycerine
NVC	Nailfold video capillaroscopy
OxLDL	Oxidised low density lipoprotein
PAI-1	Plasminogen activator inhibitor-1
PAT	Peripheral artery tonometry
PCA	Pulse curve analysis
PDGF	Platelet derived growth factor
PGO ₁	Prostacyclin

List of Abbreviations (Cont.)

RA	Rheumatoid arthritis
rDNA	recombinant DNA
RF	Rheumatoid factor
RI	Reflection index
RP	Raynaud's phenomenon
RPS	Reactive oxygen species.
RVSP	Right ventricular systolic pressure
sGC	Soluble guanylate cyclase
SLE	Systemic lupus erythematosus
SSc	Systemic sclerosis
TGF-beta	Transforming growth factor-beta
TNF	Tumor necrosis factor
To NO	Toxic nitric oxide
UIP	Usual interstitial pneumonitis
VCAM	Vascular cell adhesion molecules
VLDL	Very low density lipoproteins

Introduction

Systemic sclerosis (SSc) is a generalized autoimmune inflammatory disorder of connective tissue characterized by microvascular and immunological abnormalities, as well as increased fibroblastic activity, leading to fibrosis in the skin and various internal organs (**Andersen et al., 2000**).

In SSc, vascular involvement, particularly endothelial injury, is an early and fundamental pathogenetic step. Endothelial dysfunction, consisting in impairment of blood vessel constriction and dilation (vasomotor regulation), is followed by structural changes of arterial wall as intimal proliferation, thrombosis, and blood vessel occlusion. Vascular disease affects capillaries and arterioles, although there is an increased evidence for large-vessel involvement (**Le Roy, 1997**).

Early in the disease, peripheral microangiopathy maybe well recognized and studied by nailfold capillaroscopy, a non-invasive and safe technique that is reported to have both diagnostic and prognostic value also in the presence of isolated Raynaud's phenomenon (RP) (**Von Bierbrauer et al., 1997**).

Recently, the attention has been focused on macro-vascular disease in SSc. Morphological and functional characteristics of arteries of lower and upper limbs, carotid and coronary extramural arteries have been investigated to establish the importance and the nature of macrovascular involvement in SSc (**Szucs et al., 2007**).

Two theories of macrovascular disease have been hypothesized in SSc; the first is the extension of the vascular injury to

the macrovascular circulation, with an accelerated atherosclerosis in a pathogenesis similar to that of the microvascular damage (*Fiori et al., 2003*).

The second theory suggests that the development and acceleration of atherosclerosis in SSc can be favored by inflammation, cytokines, lipid oxidation, and autoantibodies. SSc and atherosclerosis share similar pathologic modifications of the vessel wall (*Matucci-Cerinic et al., 2003*).

Brachial artery (BA) flow-mediated vasodilation (FMD) and Carotid artery intima-media thickness (IMT) are currently used as noninvasive tests for vascular function and structure respectively, in addition to other alternative measures of subclinical atherosclerosis (*Marwick et al., 2001*).

Carotid IMT identifies early structural abnormalities of the vascular wall. Its increase correlates with cardiovascular risk factors, and is an independent predictor of cardiovascular and cerebrovascular events (*Riley et al., 2001*).

Brachial FMD measures vascular endothelial function. It also correlates with cardiovascular risk factors and it seems to have prognostic significance for vascular events (*Mancini, 2004*).

Aim of the Study

The aim of this study is to assess subclinical macrovascular involvement in SSc(using non-invasive tests) and its possible pathogenesis by correlating findings with the traditional cardiovascular risk factors and with the pattern of microvascular disease (assessed by nailfold capillaroscopy).

Systemic Sclerosis

Introduction

Scleroderma is systemic disorder of the connective tissue; manifested by hardening and thickening of the skin, by abnormalities involving the microvasculature and larger vessels, and by fibrotic degenerative changes in various body organs including the heart, lungs, kidneys, and gastrointestinal (**Charles, ٢٠٠٦**).

It is characterized by formation of hyalinized and thickened collagenous fibrous tissue, with thickening of the skin and adhesion to underlying tissues (especially of the hands and face), dysphagia due to loss of peristalsis and submucosal fibrosis of the esophagus, dyspnea due to pulmonary fibrosis, myocardial fibrosis, and renal vascular changes resembling those of malignant hypertension. Raynaud phenomenon, atrophy of the soft tissues, and osteoporosis of the distal phalanges (acrosclerosis), sometimes with gangrene at the ends of the digits, are common findings (**Sakkas, ٢٠٠٥**).

Historical aspect

Hippocrates first described this condition as thickened skin. **Carlo Curzio** (١٧٥٢) offered the first detailed description of this condition when a patient presented with hard skin, which he described as woodlike or containing a dry hide.

In ١٨٣٦, **Giovambattista Fantonetti** applied the term scleroderma to a patient's condition. He applied the term to describe a